Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma

被引：1

作者：

Lipschitz, Noga ^{[1
]}

Earl, Brian R. ^{[1
,2
]}

Cripe, Timothy P. ^{[3
,4
]}

Samy, Ravi N. ^{[1
,5
,6
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA

[2] Univ Cincinnati, Dept Commun Sci & Disorders, Coll Allied Hlth Sci, Cincinnati, OH USA

[3] Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH USA

[4] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Res Inst, Columbus, OH USA

[5] Univ Cincinnati, Neurosensory Disorders Ctr, Gardner Neurosci Inst, 213 Albert Sabin Way,MSB 6407, Cincinnati, OH 45267 USA

[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA

来源：

CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY | 2020年 / 28卷 / 05期

关键词：

cholesteatoma; herpes simplex virus; oncolytic virotherapy; TALIMOGENE LAHERPAREPVEC; ACQUIRED CHOLESTEATOMA; VIRUS; SAFETY; ADENOVIRUS; MELANOMA; EFFICACY; PATHOGENESIS; COMBINATION; HSV-1;

D O I：

10.1097/MOO.0000000000000651

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Purpose of review To review the principles of oncolytic virotherapy and summarize the recent preliminary evidence on the efficacy of oncolytic virotherapy for cholesteatoma (CHST) treatmentin vitroin human CHST cells and in a gerbil CHST model. Recent findings The use of oncolytic virotherapy for nonmalignant lesions is innovative. In-vitro results showed that oncolytic herpes simplex virus 1 (oHSV) selectively targets and kills CHST cells. In a gerbil model of CHST, local oHSV injections were associated with a decrease in CHST volume and modulation of bony changes. Surgical treatment options for CHST are limited by high morbidity and recidivism, emphasizing the need for developing treatment alternatives. Preliminary results support the potential therapeutic effect of oncolytic virotherapy on CHST, yet further research is needed to evaluate this novel approach.

引用

页码：281 / 285

页数：5

共 50 条

[1] Oncolytic Virotherapy by HSV
Watanabe, Daisuke
Goshima, Fumi
HUMAN HERPESVIRUSES, 2018, 1045 : 63 - 84
[2] Oncolytic virotherapy - a promising approach in cancer treatment
Sharma, Rohit
Sil, Debayan
Kumar, Dinesh
Komal, Kumari
Kumar, Sourabh
Ghosh, Rashmi
Saini, Vipin
Kumar, Manish
EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (04) : 315 - 318
[3] Immune System, Friend or Foe of Oncolytic Virotherapy?
Finley, Anna C.
Dey, Mahua
FRONTIERS IN ONCOLOGY, 2017, 7
[4] Tumor Tropism of DNA Viruses for Oncolytic Virotherapy
Enow, Junior A.
Sheikh, Hummad I.
Rahman, Masmudur M.
VIRUSES-BASEL, 2023, 15 (11):
[5] Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?
Soldozy, Sauson
Mulligan, Kathleen M.
Zheng, David X.
Levoska, Melissa A.
Cullison, Christopher R.
Elarjani, Turki
Eichberg, Daniel G.
Ampie, Leonel E.
Shah, Ashish H.
Yagmurlu, Kaan
Shaffrey, Mark E.
Scott, Jeffrey F.
Komotar, Ricardo J.
BRAIN SCIENCES, 2021, 11 (10)
[6] Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy
Sobol, Paul T.
Boudreau, Jeanette E.
Stephenson, Kyle
Wan, Yonghong
Lichty, Brian D.
Mossman, Karen L.
MOLECULAR THERAPY, 2011, 19 (02) : 335 - 344
[7] Oncolytic virotherapy in cancer treatment: challenges and optimization prospects
Chen, Lingjuan
Zuo, Mengsi
Zhou, Qin
Wang, Yang
FRONTIERS IN IMMUNOLOGY, 2023, 14
[8] Oncolytic virotherapy in head and neck cancer
Runge, Annette
Petersson, Monika
Riechelmann, Herbert
LARYNGO-RHINO-OTOLOGIE, 2022, 101 (10) : 787 - 796
[9] Oncolytic Virotherapy for Neuroblastoma
Ramirez, Manuel
Garcia-Castro, Javier
Alemany, Ramon
DISCOVERY MEDICINE, 2010, 10 (54) : 387 - 393
[10] The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical study
Pooladvand, Pantea
Yun, Chae-Ok
Yoon, A-Rum
Kim, Peter S.
Frascoli, Federico
MATHEMATICAL BIOSCIENCES, 2021, 334

← 1 2 3 4 5 →